Posted On: 24/09/17
We were founded in the 1970s by families of disabled children, who recognised that even if their child's conditions were different, they shared a common experience - of being a family with a disabled child. They understood how important it is to support each other.
A lot has changed since then but some things haven't changed nearly enough. There is a desperate lack of services and support for the 620,000 parents in...
Posted On: 19/09/17
Charcot-Marie-Tooth disease - an inherited neurological disorder
Estimates suggest around 25,000 people in the UK have Charcot-Marie-Tooth disease (CMT).1 They usually start to have symptoms – which can include muscle weakness and numbness in the feet, arms and hands – during childhood or adolescence. Symptoms slowly get worse and more disabling over time, making everyday tasks increasingly difficult. Professor David Bennett, of the University of Oxford, is in the early...
Posted On: 13/09/17
Across the country, thousands of children will be starting their first year at school. You may remember a school nurse asking you to tell them what you could see on a chart.
Now that I, (Donna O'Brien) work for SeeAbility, I’ve learned what was going on back then in the primary school. The school nurse had given me what is known as a ‘vision screen’.
Not only were they checking how much detail I could see with each eye and the possibility I might need glasses, they were...
Posted On: 06/09/17
The European Medicines Agency (EMA) has licensed cladribine (also known as Mavenclad) to treat people with highly active relapsing MS.
The National Institute for Health and Care Excellence (NICE) will now decide whether to make it available on the NHS in England and Wales. The Scottish Medicines Consortium (SMC) will decide for Scotland.
How does it work?
Cladribine is currently used as an anti-cancer drug.
In MS, the body's own immune cells mistakenly attack the myelin that protects...